Cover Image
市場調查報告書

EpiCast Report:亨丁頓舞蹈症 - 到2024年前的流行病學預測

EpiCast Report: Huntington's Disease - Epidemiology Forecast to 2024

出版商 GlobalData 商品編碼 349804
出版日期 內容資訊 英文 49 Pages
訂單完成後即時交付
價格
Back to Top
EpiCast Report:亨丁頓舞蹈症 - 到2024年前的流行病學預測 EpiCast Report: Huntington's Disease - Epidemiology Forecast to 2024
出版日期: 2015年12月09日 內容資訊: 英文 49 Pages
簡介

全球主要7國(美國,法國,德國,義大利,西班牙,英國,日本)確診亨丁頓舞蹈症的患者數,預測將從2014年的57,314人成長到2024年的60,743人,以0.60%的年度成長率增加。

本報告提供全球主要7個國家的亨丁頓舞蹈症調查分析,提供您疾病背景,危險因素和合併症,全球趨勢,流行病學預測等相關的系統性資訊。

第1章 目錄

第2章 簡介

第3章 流行病學

  • 疾病的背景
  • 危險因素和合併症
  • 全球趨勢
    • 主要7個國家
  • 預測手法
    • 利用之資訊來源
    • 未利用之資訊來源
    • 預測的前提條件與手法
  • 亨丁頓舞蹈症的流行病學預測
    • 確診的患者數
    • 確診的患者數 (發病各年齡)
    • 確診的患者數 (成人)
  • 議論
    • 流行病學預測相關考察
    • 分析的限制
    • 分析的優勢

第4章 附錄

圖表

目錄
Product Code: GDHCER108-15

Huntington's disease (HD) is a rare, inherited, genetic disorder that causes progressive degeneration of the nerve cells of the brain especially the caudate, the putamen, and the cerebral cortex. As the brain cells die, a person with HD is unable to control movements, recall events, make decisions, and control emotions, and the disorder leads to incapacitation, cognitive and psychiatric disorders, and eventually death. The signs and symptoms of HD mostly appear between the ages 30-40 years, although the onset of disease may occur earlier or later in life. Therefore the disease is mostly of adult onset. The average lifespan of a person after being diagnosed with adult-onset HD is about 15-20 years. When the onset of the disease begins earlier than the age 20 years, the condition is called juvenile HD. Juvenile HD presents somewhat different symptoms and has a faster disease progression.

GlobalData epidemiologists forecast an increase in the diagnosed prevalence of HD over the ten-year forecast period. The number of diagnosed prevalent cases of HD in the 7MM will increase from 57,314 cases in 2014 to 60,743 cases in 2024, with an AGR of 0.60% during the forecast period. For juvenile HD, GlobalData epidemiologists forecast an increase from 1,000 diagnosed prevalent cases in 2014 to 1,013 diagnosed prevalent cases in 2024, in the 7MM, with an AGR of 0.13%.

GlobalData epidemiologists used the available data on HD to the best extent possible to provide the most insightful epidemiological forecast for the diagnosed prevalent cases of HD, diagnosed prevalent cases of juvenile HD, diagnosed prevalent cases of HD by age at onset, and diagnosed prevalent cases of adults with juvenile-onset HD that progressed to adulthood in the 7MM. All sources for the 7MM assessed HD by diagnostic testing, including genetic tests. Additionally, the forecast methodology was kept consistent across the 7MM to allow for a meaningful comparison of the projected diagnosed prevalent cases of HD across the markets.

Scope

  • The Huntington's Disease EpiCast Report provides an overview of the risk factors, comorbidities, and global trends for Huntington's disease (HD) in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast of the diagnosed prevalent cases of HD and juvenile HD, diagnosed prevalent cases of Huntington's disease by age at onset, and diagnosed prevalent cases of adults with juvenile onset HD that progressed to adulthood, segmented by age and sex.
  • The HD epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

The Huntington's Disease EpiCast report will allow you to -

  • Develop business strategies by understanding the trends shaping and driving the global HD market.
  • Quantify patient populations in the global HD market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the sex and age groups that present the best opportunities for HD therapeutics in each of the markets covered.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports

3. Epidemiology

  • 3.1. Disease Background
  • 3.2. Risk Factors and Complications
  • 3.3. Global Trends
    • 3.3.1. Diagnosed Prevalence of Huntington's Disease - 7MM
  • 3.4. Forecast Methodology
    • 3.4.1. Sources Used
    • 3.4.2. Sources Not Used
    • 3.4.3. Forecast Assumptions and Methods
  • 3.5. Epidemiological Forecast of Huntington's Disease (2014-2024)
    • 3.5.1. Diagnosed Prevalent Cases
    • 3.5.2. Diagnosed Prevalent Cases of Huntington's Disease by Age at Onset
    • 3.5.3. Diagnosed Prevalent Cases of Adults with Juvenile Onset Huntington's Disease that Progressed to Adulthood, Ages ≥20 Years
  • 3.6. Discussion
    • 3.6.1. Epidemiological Forecast Insight
    • 3.6.2. Limitations of the Analysis
    • 3.6.3. Strengths of the Analysis

4. Appendix

  • 4.1. Bibliography
  • 4.2. About the Authors
    • 4.2.1. Epidemiologists
    • 4.2.2. Reviewers
    • 4.2.3. Global Director of Therapy Analysis and Epidemiology
    • 4.2.4. Global Head of Healthcare
  • 4.3. About GlobalData
  • 4.4. About EpiCast
  • 4.5. Disclaimer

List of Tables

  • Table 1: Risk Factors and Complications for Huntington's Disease
  • Table 2: 7MM Estimates for the Diagnosed Prevalence of Huntington's Disease
  • Table 3: 7MM, Sources of Epidemiological Data Used for the Forecast of Huntington's Disease Diagnosed Prevalent Cases
  • Table 4: 7MM, Sources of Epidemiological Data Used for the Forecast of Juvenile Huntington's Disease Diagnosed Prevalent Cases
  • Table 5: 7MM, Sources of Epidemiological Data Used for the Forecast of Huntington's Disease Diagnosed Prevalent Cases by Age at Onset
  • Table 6: 7MM, Diagnosed Prevalent Cases of Huntington's Disease, All Ages, Both Sexes, N, 2014-2024
  • Table 7: 7MM, Diagnosed Prevalent Cases of Huntington's Disease by Age Group, Both Sexes, N (%), 2014
  • Table 8: 7MM, Sex-Specific Diagnosed Prevalent Cases of Huntington's Disease, All Ages, N (%), 2014
  • Table 9: 7MM, Diagnosed Prevalent Cases of Juvenile Huntington's Disease, Age <20 Years, Both Sexes, N, 2014-2024
  • Table 10: 7MM, Age-Specific Diagnosed Prevalent Cases of Juvenile Huntington's Disease, Both Sexes, N (%), 2014
  • Table 11: 7MM, Sex-Specific Diagnosed Prevalent Cases of Juvenile Huntington's Disease, Age <20 Years, N (%), 2014
  • Table 12: 7MM, Diagnosed Prevalent Cases of Adults with Juvenile-Onset Huntington's Disease that Progressed to Adulthood, Age ≥20 Years, Both Sexes, N, 2014-2024

List of Figures

  • Figure 1: 7MM, Diagnosed Prevalent Cases of Huntington's Disease, All Ages, Both Sexes, N, 2014-2024
  • Figure 2: 7MM, Diagnosed Prevalent Cases of Huntington's Disease by Age Group, Both Sexes, N, 2014
  • Figure 3: 7MM, Diagnosed Prevalent Cases of Huntington's Disease, by Sex, All Ages, N, 2014
  • Figure 4: 7MM, Age-Standardized Diagnosed Prevalence of Huntington's Disease (%) by Sex, All Ages, 2014
  • Figure 5: 7MM, Diagnosed Prevalent Cases of Juvenile Huntington's Disease, Age <20 Years, Both Sexes, N, 2014-2024
  • Figure 6: 7MM, Diagnosed Prevalent Cases of Juvenile Huntington's Disease by Age Group, Both Sexes, N
  • Figure 7: 7MM, Diagnosed Prevalent Cases of Juvenile Huntington's Disease by Sex, Age <20 Years, N, 2014
  • Figure 8: 7MM, Diagnosed Prevalent Cases of Huntington's Disease by Age at Onset, Both Sexes, N, 2014
  • Figure 9: 7MM, Diagnosed Prevalent Cases of Adults with Juvenile-Onset Huntington's Disease that Progressed to Adulthood, Age ≥20 Years, Both Sexes, N, 2014
Back to Top